Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
December 17, 2021 18:09 ET | Zai Lab Limited
VYVGART is the first and only FDA-approved neonatal Fc receptor blocker 68% of anti-acetylcholine receptor (AChR) antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the...
Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Pemphigus
November 15, 2021 07:30 ET | Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab logo .png
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
January 06, 2021 16:01 ET | Zai Lab Limited; argenx
Collaboration to expand and accelerate global development of efgartigimod; expected to allow argenx to more rapidly advance new potential indications into clinical development each yearZai Lab granted...